Bank of America has adjusted its outlook on Sarepta Therapeutics (SRPT, Financial), reducing the price target for the biotechnology company from $179 to $157 while maintaining a Buy rating on the stock. This revision is part of a broader update of the firm’s models in the small-to-mid-cap biotech sector in anticipation of the upcoming first-quarter earnings reports.
The decision to modify the price target reflects the bank's strategic analysis within the biotech sector, which boasts a range of competitive dynamics and innovation-driven growth prospects. Despite the lowered target, the Buy rating suggests continued confidence in Sarepta's long-term performance and potential within the biotech market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for Sarepta Therapeutics Inc (SRPT, Financial) is $155.09 with a high estimate of $209.00 and a low estimate of $70.00. The average target implies an upside of 188.32% from the current price of $53.79. More detailed estimate data can be found on the Sarepta Therapeutics Inc (SRPT) Forecast page.
Based on the consensus recommendation from 25 brokerage firms, Sarepta Therapeutics Inc's (SRPT, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sarepta Therapeutics Inc (SRPT, Financial) in one year is $215.89, suggesting a upside of 301.36% from the current price of $53.79. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sarepta Therapeutics Inc (SRPT) Summary page.
